Evidence map›Paper›PMID 34055359›Full record

ArticleOxford medical case reports2021

Resolution of primary hepatic marginal zone lymphoma in a hepatitis C virus-infected patient treated with a direct-acting antiviral.

Adriano Pellicelli, Valerio Giannelli, Valerio Zoli, Giovanni Regine, Andrea Cortese, Giuseppe M Ettorre, Enrico Carmenini, Valeria Pellicelli, Luigi Rigacci

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Oxford medical case reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 92% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Adriano PellicelliLiver Unit, Department of Liver Transplant, Azienda Ospedaliera San Camillo Forlanini, Rome, Italy.
Valerio GiannelliLiver Unit, Department of Liver Transplant, Azienda Ospedaliera San Camillo Forlanini, Rome, Italy.
Valerio ZoliHematology Unit, Azienda Ospedaliera San Camillo Forlanini, Rome, Italy.
Giovanni RegineDepartment of Radiology, Azienda Ospedaliera San Camillo Forlanini, Rome, Italy.
Andrea CorteseDepartment of Radiology, Azienda Ospedaliera San Camillo Forlanini, Rome, Italy.
Giuseppe M EttorreDivision of General Surgery and Liver Transplantation, Azienda Ospedaliera San Camillo Forlanini, Rome, Italy.
Enrico CarmeniniLiver Unit, Department of Liver Transplant, Azienda Ospedaliera San Camillo Forlanini, Rome, Italy.
Valeria PellicelliInternal Medicine, Azienda Ospedaliera Sant'Andrea Università degli Studi "La Sapienza", Rome, Italy.
Luigi RigacciHematology Unit, Azienda Ospedaliera San Camillo Forlanini, Rome, Italy.
Azienda Ospedaliera San Camillo-Forlanini · ITAzienda Ospedaliera Sant'Andrea · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The favorable impact of antiviral therapy on low-grade hepatitis C virus (HCV)-related non-Hodgkin lymphoma manifesting as marginal zone lymphoma (MZL) has been reported in some clinical studies. However, primary HCV-related marginal zone lymphomas (MZLs) confined to the liver have not been described in the literature nor have the resolution of liver lymphoma through anti-HCV eradication treatment. The authors report a genotype 1b HCV-positive patient with chronic hepatitis who exhibited lesions involving both hepatic lobes resembling hepatocellular carcinoma. Liver biopsy revealed an MZL of the liver. Antiviral treatment using sofosbuvir associated with simeprevir as unique treatment was started and resulted in complete haematological response. In HCV-related MZL isolated to the liver, antiviral treatment has led to the eradication of viral infection and a complete haematological response. Antiviral therapy should be considered as a first-line treatment for HCV-related primary MZLs of the liver.

Indexed as

antiviral therapyHCV infectionliver lymphomamarginal zone lymhomasofosbuvir

Identifiers

PMID34055359
PMCPMC8143661
OpenAlexW3164264517

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.